Immune monitoring after anti-CD19 CAR T-cel therapy with patients with B-cell NH

• Conditions: B-cell NHL; 10018849; B-cell non-Hodgkin lymphoma

• Registration Number: NL-OMON56841
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 8 July 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 525

Inclusion Criteria

treatment of B-cell NHL with anti-CD19 CAR T-cel therapy

Exclusion Criteria

no informed consent

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Overall objective response rate<br /><br>Correlation of cell free tumor DNA with ORR<br /><br>T-cell persistence combined with immunological and metabolic phenotype<br /><br>Observation of T-cell immune evasion mechanisms in tumor area</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>No secondary parameters</p><br>